What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.”In the company’s words, NCT07548632 on ClinicalTrials.gov
- Tested for
- Dry Eye Disease (DED)
- Main trialPhase 2/3
- “The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.”In the company’s words, NCT07548632 on ClinicalTrials.gov
- Other names
- OCS-02
Other drugs for Dry Eye Disease (DED)
- DeucravacitinibBristol Myers Squibb · Phase 3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- CAM-101Cambium Bio Limited · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- OT202Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3
Coming up1
- DecPhase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | Dec 2026 | A Clinical Study Evaluating Licaminlimab for Dry Eye Disease | |
| Phase 2Completed | 27 Mar 2024 | Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026